Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer
- 1 January 2011
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 22 (1) , 235-237
Abstract
The RAS/MAPK pathway, together with phosphatidylinositol 3-kinase/Akt (PI3K/AKT), is the major signalling network linking epidermal growth factor receptor (EGFR) activation to cell proliferation and survival.Keywords
This publication has 5 references indexed in Scilit:
- Personalized Medicine in Non–Small-Cell Lung Cancer: Is KRAS a Useful Marker in Selecting Patients for Epidermal Growth Factor Receptor–Targeted Therapy?Journal of Clinical Oncology, 2010
- Genomic and Biological Characterization of Exon 4 KRAS Mutations in Human CancerCancer Research, 2010
- New Strategies for Treatment of KRAS Mutant Metastatic Colorectal CancerClinical Cancer Research, 2010
- Durable responses to Erlotinib despite KRAS mutations in two patients with metastatic lung adenocarcinomaAnnals of Oncology, 2010
- KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal CancerCancer Research, 2006